Grant Jeremy T. - 21 Dec 2023 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
Director
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
21 Dec 2023
Net transactions value
$0
Form type
4
Filing time
26 Dec 2023, 18:09:03 UTC
Next filing
10 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $0 +8,826 $0.000000 8,826 21 Dec 2023 Direct
transaction TBPH Ordinary Shares Award $0 +2,942 +33% $0.000000 11,768 21 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBPH Share Option (Right to Buy) Award $0 +19,734 $0.000000 19,734 21 Dec 2023 Ordinary Shares 19,734 $11.33 Direct F1
transaction TBPH Share Option (Right to Buy) Award $0 +6,578 $0.000000 6,578 21 Dec 2023 Ordinary Shares 6,578 $11.33 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests monthly over 24 months of service from the date of grant.
F2 This option shall vest monthly over four months of service from the date of grant and will vest in full upon earlier of the four-month anniversary of Jeremy Grant's appointment to the Board or the date of Company's 2024 annual meeting of Shareholders.